ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
newsfilecorp.com
Want to monitor NXTC?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor NXTCnextcure, inc. , a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors.